Prime Road’s regenerative medicine implementation support business
First written in FY2022. 6 of 11 entries say "Advanced", first in FY2023-Q1. Latest entry: 2026-08-12.
0 other companies' latest entry also says "Worsened".
- FY2026-H1AdvancedAnnual report
「Although revenue increased at プライムロード株式会社, which operates a regenerative medicine support business, following the start of its contract cell culture and processing business, profit declined due to upfront costs incurred in connection with the start of operations at the cell culture and processing facility.」
The contract cell culture and processing business planned for FY2025 began, and the company disclosed revenue recognition and upfront costs associated with the facility's start of operations. - FY2025AdvancedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, is also planning to open a cell culture and processing facility and is preparing to enter the contract cell culture and processing business.」
The company plans to expand from regenerative medicine implementation support into the contract cell culture and processing business and recorded ¥123 million in machinery, equipment, fixtures and facility construction costs during the year. - FY2024-Q2MitigatedAnnual report
「Revenue from regenerative medicine consulting services provided by プライムロード株式会社, which operates a regenerative medicine implementation support business, remained at the same level as in the corresponding period of the previous year.」
For プライムロード, which had reported a decline in orders in the previous quarter, revenue from regenerative medicine consulting services was at the same level as in the corresponding period of the previous year. - FY2024-Q1WorsenedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, also saw orders for regenerative medicine consulting services decline.」
The company reported a decline in orders for Prime Road's regenerative medicine consulting services. - FY2023AdvancedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, also saw orders for regenerative medicine consulting services increase.」
The company reported an increase in orders for regenerative medicine consulting services through Prime Road's regenerative medicine implementation support business for the full fiscal year as well. - FY2023-Q3AdvancedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, also saw orders for regenerative medicine consulting services increase.」
The company reported an increase in orders for Prime Road's regenerative medicine consulting services. - FY2023-Q2AdvancedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, also saw orders for regenerative medicine consulting services increase.」
The company reported an increase in orders for regenerative medicine consulting services through Prime Road's regenerative medicine implementation support business. - FY2023-Q1AdvancedAnnual report
「プライムロード株式会社, which operates a regenerative medicine implementation support business, also won an order for regenerative medicine consulting services.」
The company continued to report orders won for regenerative medicine consulting services through Prime Road's regenerative medicine implementation support business. - FY2022First statedAnnual report
「プライムロード株式会社 operates a regenerative medicine implementation support business that provides one-stop support to medical institutions seeking to introduce regenerative medicine. プライムロード株式会社, which operates this business, also won an order.」
Through プライムロード, established in August 2021, the company commercialized one-stop support for medical institutions seeking to introduce regenerative medicine and reported winning orders in FY2022.